Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard… - The lancet …, 2014 - thelancet.com
Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …
被引用次数：130 相关文章

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

PA Jänne, SI Ou, DW Kim, GR Oxnard… - The Lancet …, 2014 - europepmc.org
Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase …

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase …

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard, R Martins… - The Lancet …, 2014 - Elsevier
Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …

[引用][C] Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard, R Martins… - The Lancet …, 2014 - cir.nii.ac.jp
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced
non-small-cell lung cancer: a multicentre, open-label, phase 2 trial | CiNii Research CiNii 国立 …

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jaenne, SHI Ou, DW Kim, GR Oxnard… - The Lancet …, 2014 - s-space.snu.ac.kr
Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase …

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard, R Martins… - The Lancet …, 2014 - infona.pl
Patients with EGFR-mutant non-small-cell lung cancer generally have a progression-free
survival of 9–13 months while being treated with the EGFR tyrosine-kinase inhibitors …

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard… - The Lancet …, 2014 - snucm.elsevierpure.com
Background: Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9-13 months while being treated with the EGFR tyrosine-kinase …

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard… - The Lancet …, 2014 - thelancet.com
Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …

[引用][C] Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

PA Jänne, SHI Ou, DW Kim, GR Oxnard… - Lancet …, 2014 - Elsevier Limited